PI3K/Akt/mTOR Signaling
Research Areas
Products Related to PI3K/Akt/mTOR Signaling(719)
- GC14884SAR245409 (XL765)CAS: 1349796-36-6Purity: >98%
SAR245409 (XL765) (XL-147 derivative 1) is a potent inhibitor of PI3K. SAR245409 (XL765) (25 μM) blocks PI3K/Akt signaling pathways.
- GC15072GSK2126458 (Omipalisib)CAS: 1086062-66-9Purity: >99.50%
GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity.
- GC16145NVP-BGT226CAS: 1245537-68-1Purity: >99.50%
BGT226 (NVP-NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.
- GC16417PF-04691502CAS: 1013101-36-4Purity: >99.50%
PF-04691502 is an orally active, ATP-competitive dual inhibitor of PI3K and mTOR, with K i values of 1.2, 2.1, 1.6, and 1.9nM for PI3Kα, β, δ, and γ isoforms, respectively.
- GC17153CHIR-99021 (CT99021) HClCAS: 1797989-42-4Purity: >99.00%
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. CHIR-99021 (CT99021) HCl shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. CHIR-99021 (CT99021) HCl is also a potent Wnt/β-catenin signaling pathway activator. CHIR-99021 (CT99021) HCl enhances mouse and human embryonic stem cells self-renewal. CHIR-99021 (CT99021) HCl induces autophagy.
- GC17243Dorsomorphin (Compound C)CAS: 866405-64-3Purity: >98.00%
Dorsomorphin (Compound C) is an agent that used as a cell-permeable AMPK inhibitor.
- GC10195Z-GuggulsteroneCAS: 39025-23-5Purity: >98.00%
Z-Guggulsterone is a steroidal plant active ingredient derived from Commiphora mukul and can promote cancer cell apoptosis.
- GC10461Phenformin HClCAS: 834-28-6Purity: >98.00%
Phenformin HCl is an anti-diabetic drug from the biguanide class, can activate AMPK activity.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC14346 | KU-0060648 | 881375-00-4 | >99.00% | |
Dual DNA-PK/PI3-K inhibitor, ATP-competitive | ||||
| GC14884 | SAR245409 (XL765) | 1349796-36-6 | >98% | |
SAR245409 (XL765) (XL-147 derivative 1) is a potent inhibitor of PI3K. SAR245409 (XL765) (25 μM) blocks PI3K/Akt signaling pathways. | ||||
| GC15072 | GSK2126458 (Omipalisib) | 1086062-66-9 | >99.50% | |
GSK2126458 (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. GSK2126458 has anti-cancer activity. | ||||
| GC15742 | OSU-03012 (AR-12) | 742112-33-0 | >98% | |
Potent PDK1 inhibitor | ||||
| GC15864 | CCT128930 | 885499-61-6 | >99.50% | |
AKT inhibitor | ||||
| GC16145 | NVP-BGT226 | 1245537-68-1 | >99.50% | |
BGT226 (NVP-NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells. | ||||
| GC16417 | PF-04691502 | 1013101-36-4 | >99.50% | |
PF-04691502 is an orally active, ATP-competitive dual inhibitor of PI3K and mTOR, with K i values of 1.2, 2.1, 1.6, and 1.9nM for PI3Kα, β, δ, and γ isoforms, respectively. | ||||
| GC16462 | BYL-719 | 1217486-61-7 | >99.50% | |
BYL-719 is an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor that blocks the PI3K/AKT/mTOR pathway. | ||||
| GC16713 | HS-173 | 1276110-06-5 | >98.00% | |
novel PI3K inhibitor | ||||
| GC16818 | BX-912 | 702674-56-4 | >99.50% | |
PDK1 inhibitor,potent and ATP-competitive | ||||
| GC17104 | PKI-402 | 1173204-81-3 | >99.50% | |
PI3K inhibitor,selective, reversible and ATP-competitive | ||||
| GC17153 | CHIR-99021 (CT99021) HCl | 1797989-42-4 | >99.00% | |
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. CHIR-99021 (CT99021) HCl shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. CHIR-99021 (CT99021) HCl is also a potent Wnt/β-catenin signaling pathway activator. CHIR-99021 (CT99021) HCl enhances mouse and human embryonic stem cells self-renewal. CHIR-99021 (CT99021) HCl induces autophagy. | ||||
| GC17243 | Dorsomorphin (Compound C) | 866405-64-3 | >98.00% | |
Dorsomorphin (Compound C) is an agent that used as a cell-permeable AMPK inhibitor. | ||||
| GC18164 | UCB9608 | 1616413-96-7 | >99.00% | |
PI4KIIIβ inhibitor | ||||
| GC27959 | NC03 | 568558-66-7 | >98.50% | |
NC03 is a PI4K2A inhibitor and reducing agent. NC03 inhibits the activity of PI4K2A, thereby reducing the production of PI4P in the cellular compartments where PI4K2A functions. | ||||
| GA10282 | H-Leu-OH | 61-90-5 | >99.00% | |
| GC10070 | CGS 15943 | 104615-18-1 | >99.50% | |
adenosine receptor antagonist | ||||
| GC10195 | Z-Guggulsterone | 39025-23-5 | >98.00% | |
Z-Guggulsterone is a steroidal plant active ingredient derived from Commiphora mukul and can promote cancer cell apoptosis. | ||||
| GC10228 | GDC-0084 | 1382979-44-3 | >98% | |
PI3K and mTOR inhibitor, brain-permeable | ||||
| GC10336 | A 1070722 | 1384424-80-9 | >99.00% | |
GSK-3 inhibitor | ||||
| GC10340 | GNE-477 | 1032754-81-6 | >98.50% | |
dual PI3K/mTOR inhibitor | ||||
| GC10436 | VPS34-IN1 | 1383716-33-3 | >98.00% | |
Vps34 inhibitor | ||||
| GC10440 | TCS 183 | - | >98% | |
competitive inhibitor of GSK-3β (Ser9) phosphorylation | ||||
| GC10461 | Phenformin HCl | 834-28-6 | >98.00% | |
Phenformin HCl is an anti-diabetic drug from the biguanide class, can activate AMPK activity. | ||||